Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREXAFEMME is an oral small-molecule tablet approved by GSK in June 2021 for treatment in women's health. The specific indication and mechanism of action are not disclosed in available data, but the product name suggests a female-focused therapeutic area. The drug is currently in peak commercial lifecycle stage.
Peak13.1 years to LOE
Peak lifecycle stage indicates mature commercial operations with established sales infrastructure and stable team composition; no current market share pressure is evident.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BREXAFEMME offers stable, established commercial career opportunities within GSK's women's health portfolio at peak lifecycle maturity. Zero competitive pressure and strong patent protection suggest a defensible brand position with lower volatility and established team structures, making it suitable for professionals seeking operational expertise and market leadership roles rather than launch-phase intensity.
Brand Manager
Worked on BREXAFEMME at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.